Eisai

Trending Articles

  1. Touchlight becomes the first synthetic DNA API manufacturer to receive GMP certification The CDMO's Hampton, UK facility has received GMP certification to produce investigational APIs and critical starting materials for DNA vaccines and non-viral gene therapies
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Managing airflow, contamination risks and technician well-being with biological safety cabinets Microbiology labs and other facilities researching biohazardous materials and pathogens such as bacteria, viruses and fungi must avoid contamination. It is critical to ensure...
  3. Daiichi Sankyo and BioMed X Institute join forces to develop multi-specific biologics for cancer therapy Through this collaboration, they aim to discover and develop novel target combinations for bi- and multi-specific biologics for the treatment of solid tumours
  4. Teva Pharmaceuticals, Klinge Pharma and Formycon join forces to commercialise Eylea biosimilar FYB203, which will be marketed under the name AHZANTIVE®3 if approved by the EMA, will be commercialised by Teva Pharmaceuticals in the majority of Europe and Israel
  5. Vetter launches new iteration of the V-OVS syringe closure system The new version is optimised to protect the integrity of the injectable product with easier handling characteristics and an intuitive opening mechanism

Upcoming event

Pharmapack

22 – 23 January 2025 | Exhibition | Paris, France See all

Related Content

Regulatory

Alzheimer's drug lecanemab deemed unsuitable for the UK NHS by health regulator

The drug will not be available on the NHS owing to significant and potentially life-threatening side effects, as well as the cost of the medicine and its limited efficacy
Regulatory

FDA grants landmark approval for Alzheimer’s treatment

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease
Regulatory

AbbVie and Eisai launch online Humira support tool service

The free-of-charge service assists patients on Humira therapy by delivering support tools to their home or other requested location
Finance

Eisai and Fuji Yakuhin sign ASEAN distribution agreement for gout therapy

Hyperuricemia is known to be associated with various diseases in the urinary system, endocrine system, metabolic system, cardio-cerebrovascular system etc., including gout
Research & Development

Eisai and Biogen announce Phase IV Alzheimer's study design

The companies will be evaluating the long-term effectiveness and safety data of Biogen's Alzheimer's therapy, Aduhelm
Regulatory

Eisai and Merck combination cancer therapy approved by FDA

The approval for this population is based on results from a Phase III Study 309/KEYNOTE-775 trial
Research & Development

Eisai makes major investments in drug creation

Platform will be established to combine Eisaid know-how with external big data and genomic data for drug innovation in neurology and oncology
Subscribe now